Skip Navigation



Journal of Biochemistry Advance Access published online on December 8, 2008
Journal of Biochemistry, doi:10.1093/jb/mvn164
This Article
Right arrow Advance Access manuscript (PDF)
Right arrow All Versions of this Article:
145/2/239    most recent
mvn164v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Mikami, Y.
Right arrow Articles by Takagi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mikami, Y.
Right arrow Articles by Takagi, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The authors 2008. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.

A new synthetic compound, SST-VEDI-1, inhibits osteoblast differentiation with a down-regulation of the Osterix expression

Yoshikazu Mikami1,2,*, Masanori Somei3 and Minoru Takagi1,2

1Department of Anatomy, 2Division of Functional Morphology, Dental Research Center, Nihon University School of Dentistry, 1-8-13 Kanda-surugadai, Chiyoda-ku, Tokyo 101-8310, Japan. 3Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma, Kanazawa, Ishikawa 920-1192, Japan.

*Corresponding author: Yoshikazu Mikami E-mail address: mikami-t{at}dent.nihon-u.ac.jp (Y. Mikami)

Received September 24, 2008; Accepted November 19, 2008


  Abstract

SST-VEDI-1(VEDI-1) is a new synthetic compound which is synthesized from tryptamine. However the effect of VEDI-1 on various bio-phenomena in cells has not yet been examined. Tryptamine is one of the known trace amines. Trace amines are present in the central nervous system at very low concentrations and they are generally considered to have potent sympathomimetic actions. On the other hand, SSH-BMI and SSH-BMII-type compounds have been demonstrated to stimulate osteoblast activity in the cultured scales of goldfish. These compounds are also synthesized from tryptamine. VEDI-1 has a similar chemical structure to that of SSH-BMI and SSH-BMII-type compounds. Therefore, this study examined the effect of VEDI-1 on osteoblastic differentiation.

VEDI-1 inhibited the osteoblast differentiation identified by mineralization, which was accompanied by the down-regulation of the expression of an osteogenic transcription factor, Osterix. Furthermore, as well as VEDI-1-treatment, the suppression of the OSX expression by stable-transfection with OSX/shRNA decreased the formation of mineralized nodules. These results suggest a possibility that VEDI-1 inhibits the osteoblast differentiation by suppressing the OSX expression.

Key Words: SST-VEDI-1, Osteoblast, Mineralization, Osterix, Differentiation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.